Status:
ACTIVE_NOT_RECRUITING
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
Lead Sponsor:
University of Cologne
Conditions:
Classical Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The aim of the trial is to improve efficacy of nivolumab in patients with relapsed or refractory HL who recently progressed on anti-PD1 therapy. Nivolumab is highly effective and well tolerated in rrH...
Eligibility Criteria
Inclusion
- Progression of refractory or relapsed cHL during treatment with an anti-PD1 agent
- At least two distinct FDG-avid HL-lesions with at least 5 cm distance between them, and one of them considered eligible for irradiation with 20Gy based on localization and prior RT exposure
- Age at registration ≥ 18 years
Exclusion
- Nodular-lymphocyte predominant HL (NLPHL) or composite/greyzone lymphoma
- Lymphoma involving the central nervous system
- Naïve to treatment with anti-PD1 targeting antibodies
Key Trial Info
Start Date :
December 5 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 4 2025
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03480334
Start Date
December 5 2019
End Date
May 4 2025
Last Update
April 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1st Department of Medicine, Cologne University Hospital
Cologne, Germany